Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00948987
Other study ID # 801907
Secondary ID 0926
Status Completed
Phase Phase 1
First received July 29, 2009
Last updated October 14, 2009
Start date September 2004
Est. completion date October 2009

Study information

Verified date October 2009
Source University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this research is to study why some people do not respond to the benefits of aspirin therapy. The benefit of aspirin is cardioprotection, or decreasing the risk of heart attack and/or stroke. Aspirin works by disabling the platelets, part of the blood cells used in clotting, from sticking together and forming blood clots, thus protecting the heart. It has been observed that failure to respond to aspirin therapy occurs in about 10% of the general population and that despite taking aspirin everyday, this group of non- responders is not getting protection for their heart. The investigators would like to determine why and how this happens.


Recruitment information / eligibility

Status Completed
Enrollment 400
Est. completion date October 2009
Est. primary completion date October 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Age between 18 - 55

- Subjects must be in good health as based on medical history, physical examination, vital signs, and laboratory tests.

- All subjects must be non- smoking volunteers

- Female subjects of child bearing potential must be using a medically acceptable method of contraception (oral contraception, depo-provera injection, IUD, condom with spermicide, diaphragm, cervical cap, progestin implant, abstinence, tubal ligation, oophorectomy, TAH) throughout the entire study period. All female subjects must consent to a urine pregnancy test at screening and just prior to the start of each treatment phase of the study, which must be negative at all time points.

- Subjects must be within 30% of their ideal body weight.

Exclusion Criteria:

- Female subjects who are pregnant or nursing a child.

- Subjects, who have received an experimental drug, used an experimental medical device within 30 days prior to screening, or who gave a blood donation of = one pint within 8 weeks prior to screening.

- Subjects with any coagulation, bleeding or blood disorders.

- Subjects who are sensitive or allergic to aspirin as well as any of their components.

- Subjects with documented history of any gastrointestinal disorders, including bleeding ulcers.

- Subjects with any evidence of cancer.

- Subjects with a history of heart disease, including myocardial infarction, angina, coronary artery disease, any evidence of coronary artery stenosis, arrhythmias, heart failure, having had a CABG

- Subjects with renal, hepatic, respiratory, endocrine, metabolic, hematopoietic or neurological disorder.

- Subjects with any abnormal laboratory value or physical finding that according to the investigator may interfere with interpretation of the study results, be indicative of an underlying disease state, or compromise the safety of a potential subject.

- Subjects who have had a history of drug or alcohol abuse within the last 6 months.

Study Design

Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Aspirin
325 mg enteric coated single dose p.o.

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
University of Pennsylvania Bayer, National Institutes of Health (NIH)

Outcome

Type Measure Description Time frame Safety issue
Primary Arachidonic acid induced platelet aggregation 8 hours postdose No
Secondary Serum thromboxane B2 concentration Urinary 11-dehydro thromboxane B2 concentration Urinary 2,3 dinor-6 keto PGF1a concentration 8 hours postdose No
See also
  Status Clinical Trial Phase
Completed NCT01432652 - The Efficacy of Aspirin in the Postoperative Period in Vascular Surgery N/A
Unknown status NCT01935193 - Aspirin Resistance Reversibility in Diabetic Patients Phase 4
Not yet recruiting NCT01547039 - Platelet Reactivity and MES During CEA N/A
Completed NCT01159639 - Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting Phase 4
Completed NCT00792272 - Prevalence and Profile of Aspirin Resistance in Hemodialysis Patients N/A
Completed NCT00466154 - The Effect of Serum LDL Lowering on Aspirin Resistance N/A
Completed NCT01104441 - Aspirin Resistance and Prognosis of Patients With Critical Limb Ischaemia